Speakers

Sarah Ikenberry is an established communication and stakeholder engagement professional with 20+ years of experience in positions of increasing responsibility. Her experience and skillset include strategic communications, marketing campaigns, stakeholder engagement, and contract and project management.

Over the last 6+ years, she has specialized in communication and stakeholder engagement for biosimilars at FDA’s Office of Therapeutic Biologics and Biosimilars (OTBB). In both her current role of Associate Director for Stakeholder Engagement and Education and her previous role as OTBB’s Senior Communication Advisor, in the Food and Drug Administration’s (FDA), Center for Evaluation and Research (CDER), she provides communication advice and support to senior leaders and the agency about communicating strategic priorities, initiatives and educational information about biosimilar and interchangeable products.

Sarah previously worked in CDER’s Office of Communications where she managed high-priority, complex issues with responsibility for planning and implementing strategic communication strategies and marketing activities designed to inform and educate the public about policy matters and health and regulatory issues related to drug products. While there, she also helped develop and launch FDA’s first campaign about biosimilar and interchangeable products.

In her Federal career, she also held positions at FDA’s Center for Devices and Radiological Health (CDRH) and the Substance Abuse and Mental Health Service Administration’s Center for Substance Abuse Treatment (CSAT). At CSAT, she worked on the Recovery Month campaign, a national health communication program and campaign for awareness and public education about substance use disorders, including, prescription drugs abuse, tobacco and alcohol. She also worked at CSAT’s Division of Pharmacologic Therapies, specializing in regulatory and communication aspects for medication assisted treatment.